Isolated axial PsA and eventual development of peripheral diseaseSeptember 16, 2022Psoriatic Arthritis
Sustained response at 2 years reported for newly approved oral psoriasis agentSeptember 15, 2022Psoriatic Arthritis
FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasisSeptember 12, 2022Psoriatic Arthritis
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?September 8, 2022Psoriatic Arthritis
Commentary: IL-Targeted Therapies and Nail Dystrophy in PsA, September 2022August 31, 2022Psoriatic Arthritis
OMERACT continues to set standards on research outcomes, enhancing the patient voiceAugust 30, 2022Psoriatic Arthritis
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depthAugust 29, 2022Psoriatic Arthritis
PsA remission depends on patient perception and is multidimensionalAugust 21, 2022Psoriatic Arthritis
